Long-term effects of intravenous pamidronate in fibrous dysplasia of bone

Journal of Bone and Mineral Research

Volumn 12, Issue 10, 1997, Pages 1746-1752

  Chapurlat, Roland D ^a   Delmas, Pierre D ^a,b   Liens, Daniel ^a   Meunier, Pierre J ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN; HYDROXYPROLINE; PAMIDRONIC ACID;

ADULT; ARTICLE; BONE PAIN; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; FEMALE; FEVER; FIBROUS DYSPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BIOPSY; BONE AND BONES; BONE DENSITY; BONE REMODELING; CALCIUM, DIETARY; DIPHOSPHONATES; FEMALE; FIBROUS DYSPLASIA OF BONE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; VITAMIN D;

EID: 0030773954     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1997.12.10.1746     Document Type: Article

References (38)

1. Lichtenstein L, Jaffé HL 1942 Fibrous dysplasia of bone. Arch Pathol 33:777-816.
2. Coley B 1960 Neoplasms of bone and related conditions, Vol 1. Paul Hocher Inc., New York, NY, U.S.A.
3. Harris WH, Dudley HR, Barry MD 1962 The natural history of fibrous dysplasia. J Bone Joint Surg 44A:207-233.
4. Firat D, Stutzman L 1968 Fibrous dysplasia of the bone: Review of twenty-four cases. Am J Med 44:421-429.
5. Henry A 1969 Monostotic fibrous dysplasia. J Bone Joint Surg 51B:300-306.
6. Albright F, Butler AM, Hampton AO, Smith P 1937 Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. N Engl J Med 216:727-746.
7. Ruggieri P, Sim FH, Bond JR, Unni KK 1994 Malignancies in fibrous dysplasia. Cancer 73:1411-1424.
8. Malloy PC, Scott WW, Hruban RH 1993 Case report 769. Skeletal Radiol 22:66-69.
9. Daffner RH, Kirks DR, Gehweiler JA, Heaston DK 1982 Computed tomography of fibrous dysplasia. Am J Roentgen 8:939-943.
10. Utz JA, Kransdorf MJ, Jelinek JS, Moser RP, Berrey BH 1989 MR appearance of fibrous dysplasia. J Comput Assist Tomogr 13:845-851.
11. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel MA 1991 Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695.
12. Candeliere GA, Glorieux FH, Prud'homme J, Saint-Arnaud R 1995 Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 332: 1546-1551.
13. Malchoff CD, Reardon G, Mc Gillivray DC, Yamase H, Rogol AD, Malchoff DM 1994 An unusual presentation of McCune-Albright syndrome confirmed by an activating mutation of the Gs α-subunit from a bone lesion. J Clin Endocrinol Metab 78:803-806.
14. Dötsch J, Kiess W, Hänze J, Repp R, Lüdecke D, Blum WF, Rascher W 1996 Gsα mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright syndrome. J Clin Endocrinol Metab 81:3839-3842.
15. Kaplan FS, Fallon MD, Boden SD, Schmidt R, Senoir M, Haddad JG 1988 Estrogen receptors in bone in a patient with polyostotic fibrous dysplasia (McCune-Albright syndrome). N Engl J Med 18:421-425.
16. Reed RJ 1963 Fibrous dysplasia of bone: A review of 25 cases. Arch Pathol 75:480-495.
17. Yamamoto K, Maeyaa I, Kishimoto M 1983 Suppressive effect of elcatonin, an eel calcitonin analogue, on excessive hydroxyproline excretion in polyostotic fibrous dysplasia (Mc-Cune-Albright's syndrome). Endocrinol Jpn 30:651-656.
18. Yamamoto T, Ozono K, Kayasama S, Yoh K, Hiroshima K, Takagi M, Matsumoto S, Michigami T, Yamaoka K, Kishimoto T, Okada S 1996 Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with Mc-Cune-Albright syndrome. J Clin Invest 98:30-35.
19. Stephenson RB, London MD, Hankin FM, Kaufert H 1987 Fibrous dysplasia: an analysis of options for treatment. J Bone Joint Surg 69A:400-409.
20. Bell NH, Avery S, Johnston CC Jr 1970 Effects of calcitonin in Paget's disease and polyostotic fibrous dysplasia. J Clin Endocrinol Metab 31:283-290.
21. Long A, Longhlin T, Towers RP, Mc Kenna TJ 1988 Polyostotic fibrous dysplasia with contrasting responses to calcitonin and mythramycin; aetiological and therapeutic implications. Int J Med Sci 157(7):229-234.
22. Liens D, Delmas PD, Meunier PJ 1994 Long-term effects of pamidronate in fibrous dysplasia. Lancet 343:953-954.
23. Garnero P, Gineyts E, Riou JP, Delmas PD 1994 Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785.
24. Morii H, Tanae A, Ibayashi H, Nakao F 1971 Effects of calcitonin in metastatic bone carcinoma, osteoporosis, polyostotic fibrous dysplasia and hypercalcemia. Endocrinol Jpn 18:81-90.
25. Helmstedt A, Ljunghall S 1979 A case of Albright's syndrome treated with calcitonin. Acta Orthop Scand 50:251-253.
26. Long A, Longhlin T, Towers RP, Mc Kenna TJ 1988 Polyostotic fibrous dysplasia with contrasting response to calcitonin and mythramycin: Aetiological and therapeutic implications. Int J Med Sci 157:229-234.
27. Fleisch H 1989 Bisphosphonates: A new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res 116:1-28.
28. Bijvoet OLM 1991 Disodium pamidronate therapy of Paget's disease. In: Singer FR, Wallach S (eds.) Paget's Disease of Bone. Elsevier Science Publishing Co., New York, NY, U.S.A., pp. 100-111.
29. Meunier PJ, Vignot E 1995 Therapeutic strategy in Paget's disease of bone. Bone 17:(Suppl):489-492.
30. Ralston SH, Gallagher SJ, Patel U 1989 Comparison of three intravenous biphosphonates in cancer associated hypercalcemia. Lancet 1:1180-1182.
31. Van Breukelen FIM, Bijvoet OLM, Van Oosternon AT 1979 Inhibition of osteolytic bone lesions by (3 amino 1 hydroxypropylilidene) 1.1 bisphosphonate (APD). Lancet 1:803-805.
32. Burckhardt P, Thiébaud D, Pery L, Von Fliedner V 1989 Treatment of tumor induced osteolysis by APD. Recent Results Cancer Res 116:54-66.
33. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, et al. for the Myeloma Study Group 1996 Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488-493.
34. Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J 1994 Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 79:1595-1599.
35. Valkema R, Vismans FJFE, Papapoulos SE, Pauwels EKJ, Bijvoet OLM 1989 Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the biphosphonate APD. Bone Miner 5:183-192.
36. Mautalen CA, Casco CA, Gonzalez D, Ghiringhelli GR, Massironi C 1984 Side effects of disodium aminohydroxypropylidene biphosphonate (APD) during treatment of bone diseases. Br Med J 288:828-829.
37. Fitton A, Mc Tavish D 1991: Pamidronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289-318.
38. Jiang Y, Zhao J, Van Holsbeeck M 1993 Effects of tiludronate on growing bone of baboons: Radiology-pathology correlation. Calcif Tissue Int 52(Suppl 2):S46 (abstract 128).